ATLANTA/PRNewswire/ -- The advanced functionality of
Elekta's family of digital linear accelerators demands the highest degree of
intelligent coordination. Elekta's latest control system, Integrity™ R1.1,
meets this requirement through three tiers of safety, command of MLC
interdigitation for exceptional field shaping, and support of virtually
limitless options to adjust the radiation dose.
Integrity
R1.1 has undergone rigorous tests in eight international centers, which
demonstrated safe reductions in treatment delivery times of as high as 30
percent. The receipt of 510(k) clearance for Integrity R1.1 enables U.S. medical
centers to realize these treatment speed and safety benefits when Elekta begins
delivery of the control systems.
"I appreciate the use of multiple measures to ensure
correct treatment delivery," says Jonas Fontenot, Ph.D., physicist at Mary Bird Perkins Cancer
Center (Baton Rouge, La.),
which has been evaluating a previous release of Integrity since February 2011.
"In addition, during Volumetric Modulated Radiation Therapy [VMAT],
Integrity constantly captures delivery parameters and sends them back to our MOSAIQ®
oncology information system, where they become part of the patient's
electronic record."
Interdigitation and Continuously Variable Dose Rate (CVDR)
boost efficiency
With interdigitation of MLCi2 enabled by Integrity R1.1, MLC capabilities have
caught up with the ability of the treatment planning system to create fields
with complex geometry. Because MLC leaves can move past one another – or
interdigitate – clinicians can employ island fields in difficult cases, such as
those involving multiple targets.
"Interdigitation is important for treating multiple
targets – such as multiple brain mets – and also when there is a target
geometry that consists of different dose objectives," Dr. Fontenot says.
"For example, we may want to treat a primary target to 70 Gy and a nodal
region to 57 Gy."
Quicker, smoother VMAT
Integrity R1.1 supports CVDR, which allows the dose rate to be adjusted to its
ideal value during delivery of both dynamic and VMAT prescriptions. This option
makes prescription delivery smoother and faster when compared to previous
discrete dose rates.
"The additional dose rate options permit the control
system to easily navigate complex dose modulation paths," he explains.
"Less variability in gantry speed smoothes VMAT arc motion, which also
translates to reduced delivery times."
Learn more at www.elekta.com/integrity.
Approval of indications may vary between different
countries. Additional regulatory clearances may be required in some
markets.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are
used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on the Nordic Exchange under the ticker EKTAb.
Website: www.elekta.com.